Cronos Group

Global Cannabis Legalization Will Expand Wellness And Medicine Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

24 Aug 25

Updated

28 Aug 25

AnalystHighTarget's Fair Value

CA$5.00

29.2% undervalued

28 Aug

CA$3.54

19.2%

-0.3%

19.2%

-0.3%

Author's Valuation

CA$5.0

29.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

CA$5.0

29.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

5.96%

Pharma revenue growth rate

0.59%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

5.97%

Calculation

US$52.31m

Earnings '28

31.59x

PE Ratio '28

US$1.65b

Market Cap '28

US$1.65b

Market Cap '28

384.88m

No. shares '28

US$4.29

Share Price '28

US$4.29 Share Price '28

Discounted to 2025 @ 5.97% p.a.

US$3.61

Fair Value '25

US$3.61 Fair Value '25

Converted to CAD @ 1.3788 USD/CAD Exchange Rate

CA$4.98

Fair Value '25